コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 oarterial, venovenous, venovenoarterial, and arteriovenous.
8 ia-induced blood flow through intrapulmonary arteriovenous anastomoses (QIPAVA ) are currently unknow
9 increased blood flow through intrapulmonary arteriovenous anastomoses (QIPAVA ) in healthy humans at
10 d the safety and efficacy of a central iliac arteriovenous anastomosis to alter the mechanical arteri
12 icate that aplexone differentially regulates arteriovenous angiogenesis by targeting the HMG-CoA redu
13 79; P=0.017); among the 198 patients with an arteriovenous (AV) access at randomization, the risk was
16 ysis vascular access recommendations promote arteriovenous (AV) fistulas first; however, it may not b
17 nal drug release in the context of synthetic arteriovenous (AV) grafts used for chronic hemodialysis.
22 (AVMs) are tortuous vessels characterized by arteriovenous (AV) shunts, which displace capillaries an
24 esence of unstable bradycardia or high-grade arteriovenous block in the absence of myocardial dysfunc
25 esence of unstable bradycardia or high-grade arteriovenous block without significant alteration in ca
28 al strategies to reduce lung stretch include arteriovenous carbon dioxide removal (AVCO2R), and high
31 drains visceral fat, we determined adipokine arteriovenous concentration differences across visceral
32 ing was examined by measuring differences in arteriovenous concentrations across the forearm muscle.
33 ight lean subjects were studied by measuring arteriovenous concentrations of metabolites and ATBF on
36 vicular arteries and veins was measured with arteriovenous contrast ratio (AVCR) and contrast-to-nois
37 in a 1:1 ratio to undergo implantation of an arteriovenous coupler device plus current pharmaceutical
38 ssure reduced by 26.9 (SD 23.9) mm Hg in the arteriovenous coupler group (p<0.0001) and by 3.7 (21.2)
39 e reduced by 13.5 (18.8) mm Hg (p<0.0001) in arteriovenous coupler recipients and by 0.5 (15.8) mm Hg
40 (43%) of 195 patients screened were assigned arteriovenous coupler therapy (n=44) or normal care (n=3
43 tially regulated by the HMGCR pathway via an arteriovenous-dependent requirement for protein prenylat
44 rresponding experimental measurements of the arteriovenous difference across the abdominal subcutaneo
45 a combination of stable isotope labeling and arteriovenous difference measurements to elucidate pathw
46 Glucose metabolism was assessed using the arteriovenous difference technique, and molecular signal
47 clamp, TNF-alpha perfusion increased glucose arteriovenous differences (0.91 +/- 0.17 vs. 0.74 +/- 0.
49 omprehensive biochemical characterization of arteriovenous differences has not yet been reported.
53 icial placenta strategies have been based on arteriovenous ECLS using the umbilical vessels with mode
54 involvement of PTPN14 in angiogenesis and/or arteriovenous fate, acting via EphrinB2 and ACVRL1/activ
57 CorMatrix wrapped around the outflow vein of arteriovenous fistula (AVF) at the time of creation coul
58 patients initiate hemodialysis (HD) with an arteriovenous fistula (AVF) in countries with universal
62 of the competing risk of death, high rate of arteriovenous fistula (AVF) maturation failure, and poor
64 and subsequently undergo placement of a new arteriovenous fistula (AVF) or arteriovenous graft (AVG)
65 enefit when initiating hemodialysis (HD) via arteriovenous fistula (AVF) or arteriovenous graft (AVG)
66 c variability in both incident and prevalent arteriovenous fistula (AVF) use among patients with ESRD
67 senting at least one cerebral or spinal pial arteriovenous fistula (AVF), and to describe their clini
68 g incident dialysis patients: (1) placing an arteriovenous fistula (AVF1st) as the initial access fol
70 ge, cerebrovascular malformations, and dural arteriovenous fistula affecting the basal ganglia, their
71 ux hemodialysis may benefit patients with an arteriovenous fistula and patients with diabetes and tha
72 Clinical practice guidelines recommend an arteriovenous fistula as the preferred vascular access f
73 ing primary radiocephalic or brachiocephalic arteriovenous fistula creation were randomly assigned (1
74 of MCP-1 occurs in the venous segment of an arteriovenous fistula in rodents, and this vasculopathic
80 effect on mortality of programmed VA (PVA), (arteriovenous fistula or PTFE graft) and nonprogrammed V
81 nd angiography revealed a pseudoaneurysm and arteriovenous fistula originating from the right interna
85 alendar year with elective open AAA repairs, arteriovenous fistula repairs, or carotid endarderectomy
86 t pulsatile tinnitus caused by a small dural arteriovenous fistula revealed in computed tomography an
87 es after ligation injury and in failed human arteriovenous fistula samples after occlusion by dediffe
88 the lower risk of mortality associated with arteriovenous fistula use in hemodialysis patients is du
92 jacent to vessels, and PSAs with concomitant arteriovenous fistula were referred to MC (n=145, 34%).
93 d by a kink, complete venous thrombosis, and arteriovenous fistula with pseudoaneurysm formation.
94 ssociations between type of vascular access (arteriovenous fistula, arteriovenous graft, and central
95 e prognosis when compared with those with an arteriovenous fistula, but the role of vascular access (
97 left heart failure, high cardiac output from arteriovenous fistula, hypoxic lung diseases, and metabo
98 n the venous segment of a murine model of an arteriovenous fistula, monocyte chemoattractant protein-
111 are causes of tinnitus include cranial dural arteriovenous fistulas (DAVFs), which are usually small
115 vascular lesions such as pseudoaneurysms and arteriovenous fistulas associated with the internal pude
116 ces the frequency of early thrombosis of new arteriovenous fistulas but does not increase the proport
117 The relative rate of thrombosis of native arteriovenous fistulas for the highest quartile of intra
118 nts needing hemodialysis are advised to have arteriovenous fistulas rather than catheters because of
119 llow-up clinically and radiologically, dural arteriovenous fistulas should be kept in mind in the eti
121 -dependent when waitlisted, individuals with arteriovenous fistulas were significantly less likely th
122 tained vascular injuries (pseudoaneurysms or arteriovenous fistulas) that can be treated electively o
124 ures observed in dysfunctional, hemodialysis arteriovenous fistulas, and that venous neointimal hyper
125 In arteriovenous malformations and dural arteriovenous fistulas, ASL is very sensitive to detect
126 of patients 3 months after implantation) for arteriovenous fistulas, averaged across all patient popu
127 s thrombosis and dysfunction of hemodialysis arteriovenous fistulas, the latter caused, in part, by t
128 ith the low-flux group for the subgroup with arteriovenous fistulas, which constituted 82% of the stu
129 ears) with CKD undergoing predialysis AVF or arteriovenous graft (AVG) creation from 2004 to 2009, an
130 ysis (HD) via arteriovenous fistula (AVF) or arteriovenous graft (AVG) vs hemodialysis catheter (HC),
134 of intradialytic hypotension with prosthetic arteriovenous graft thrombosis after multivariable adjus
135 ven twice daily after the placement of a new arteriovenous graft until the primary outcome, loss of p
136 e of vascular access (arteriovenous fistula, arteriovenous graft, and central venous catheter) and ri
141 graft patency of newly created hemodialysis arteriovenous grafts, but the individual contributions o
142 The leading cause of failure of a prosthetic arteriovenous hemodialysis-access graft is venous anasto
144 ation is associated with acquisition of dual arteriovenous identity; increased Eph-B activity improve
146 n about whether to treat an unruptured brain arteriovenous malformation (AVM) depends on a comparison
152 better outcome prediction for patients with arteriovenous malformation (AVM)-related intracerebral h
155 RASA1 mutations cause capillary malformation-arteriovenous malformation (CM-AVM); whether it also fun
159 ovascular accident caused by a right pontine arteriovenous malformation and destruction of the right
161 data regarding factors associated with brain arteriovenous malformation hemorrhage and different trea
162 al and genetic factors associated with brain arteriovenous malformation hemorrhage, as well as studie
168 ients (>/=18 years) with an unruptured brain arteriovenous malformation were enrolled into this trial
169 stroke in patients with an unruptured brain arteriovenous malformation who are allocated to either m
170 n 21 subjects with epilepsy, brain tumor, or arteriovenous malformation who had undergone IAP and MEG
171 cally associated with capillary malformation-arteriovenous malformation, but sporadic reports of lymp
172 rhage, including age at initial diagnosis of arteriovenous malformation, co-existing extranidal aneur
190 age (ICH) for patients with unruptured brain arteriovenous malformations (AVMs) in the natural course
200 nterventional treatment for unruptured brain arteriovenous malformations (bAVMs) is uncertain because
203 ss is a recognized complication of pulmonary arteriovenous malformations (PAVMs) that allow systemic
204 Mice mutant for Notch1 and Notch3 develop arteriovenous malformations and display hallmarks of the
206 f some other conditions, such as parenchymal arteriovenous malformations and intracerebral hemorrhage
207 y related Fox transcription factors, exhibit arteriovenous malformations and lack of induction of art
210 or stroke in patients with unruptured brain arteriovenous malformations followed up for 33 months.
212 areful angiographic assessment of individual arteriovenous malformations should be performed before e
214 icentre randomized trial of unruptured brain arteriovenous malformations) will be of major importance
217 estigate the proper management of unruptured arteriovenous malformations, and the key factors in endo
218 s achieved satisfactory obliteration of deep arteriovenous malformations, but with increased actuaria
219 This resulted in defective angiogenesis and arteriovenous malformations, leading to embryonic lethal
220 st the hypothesis that, for unruptured brain arteriovenous malformations, there is no difference betw
221 levant for understanding the causes of human arteriovenous malformations, tumor angiogenesis, and dia
222 hese conditions include renal hemangiomas or arteriovenous malformations, ureteropelvic junction obst
226 Final histology showed that 2 patients had arteriovenous malformations: one had a benign hemangioma
228 ngiopoietins was measured by unique, dynamic arteriovenous measurements over the reperfused kidney.
231 riolar signs (focal arteriolar narrowing and arteriovenous nicking) and retinopathy lesions (retinal
232 se: retinopathy, focal arteriolar narrowing, arteriovenous nicking, and the arteriovenous ratio--the
236 segment close to a retinal arteriole without arteriovenous overlap were imaged by adaptive optics ima
237 ension (PVO2), venous oxygen content (CVO2), arteriovenous oxygen content difference (AVDO2), and loc
238 de tension difference (P(v - a)Co2) over the arteriovenous oxygen content difference (C(a - v)o2).
239 as the products of F and O2A, and F and the arteriovenous oxygen content difference (O2A-V), respect
245 ed from linearity between heart-rate and the arteriovenous oxygen difference, present in data from ex
246 alization increased peak arterial oxygen and arteriovenous oxygen difference, whereas exercise traini
247 P(bt)O2 and the product of CBF and cerebral arteriovenous oxygen tension difference (AVTO2), suggest
249 xygen, chorioretinal vascular P(O2) and mean arteriovenous P(O2) differences decreased compared with
254 P1 cytoplasmic domain is required for normal arteriovenous patterning, because arteries and veins cro
256 iations between MRI findings and the smaller arteriovenous ratio (per standard deviation decrease): p
257 ce or to find a difference in retinal vessel arteriovenous ratio between smokers and nonsmokers (P =
258 ar narrowing, arteriovenous nicking, and the arteriovenous ratio--the last based upon semiautomated m
260 the absence of both capillary expansion and arteriovenous remodeling in serially imaged individual T
261 etric changes in neocapillary morphogenesis, arteriovenous remodeling, and microvessel regression.
263 ed the feasibility of IF measurement with an arteriovenous shunt and a coincidence counter in mice an
267 put and oxygen delivery , the creation of an arteriovenous shunt in the setting of severe chronic obs
269 Parenchymal chamber pressure generated in an arteriovenous shunt model is a critical parameter that a
275 oregulatory defences in humans are sweating, arteriovenous shunt vasoconstriction, and shivering.
276 THODS AND An ex vivo porcine carotid jugular arteriovenous shunt was established and connected to SYL
280 loped hallmarks of BAVMs, including cerebral arteriovenous shunting and vessel enlargement, by 3 week
281 lly decreased or eliminated exercise-induced arteriovenous shunting in all subjects at submaximal and
283 2 min; breathing room air, FIO2 = 0.209) and arteriovenous shunting was evaluated using saline contra
285 20) were obesity (31%), liver disease (23%), arteriovenous shunts (23%), lung disease (16%), and myel
286 l-grade tubing and catheters, assembled into arteriovenous shunts and implanted in pigs, remain paten
288 rn is not suggestive for neoangiogenesis, as arteriovenous shunts from malignant tissues are responsi
289 ollagen-coated vascular grafts inserted into arteriovenous shunts in baboons, and reduced fibrin and
290 supplemented with bovine serum, implanted as arteriovenous shunts, and assessed for both mechanical s
292 bnormalities (retinal-choroidal anastomoses, arteriovenous shunts, increased permeability, dilation,
294 al floor of the dorsal aorta concurrent with arteriovenous specification and intersegmental vessel (I
296 included hypervascularization and defects in arteriovenous specification, as well as the presence of
298 development often occurs after placement of arteriovenous synthetic grafts used for hemodialysis.
299 r, the development of hyperplasia within the arteriovenous synthetic grafts was unchanged by treatmen
300 nges include venous-venous shunting, delayed arteriovenous transit, and delayed or absent choroidal p
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。